Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Alkermes plc stock logo
ALKS
Alkermes
$29.35
+0.3%
$29.87
$22.90
$36.45
$4.83B0.471.72 million shs1.76 million shs
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
$179.10
+1.9%
$165.82
$111.09
$183.00
$10.75B0.37494,093 shs377,009 shs
Cerevel Therapeutics Holdings, Inc. stock logo
CERE
Cerevel Therapeutics
$44.96
$43.67
$19.59
$44.99
$8.19B1.41.71 million shsN/A
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
$13.52
+1.3%
$12.04
$8.02
$18.23
$6.63B1.675.22 million shs5.96 million shs
These 7 Stocks Will Be Magnificent in 2025 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Alkermes plc stock logo
ALKS
Alkermes
+0.31%-1.41%0.00%-12.88%+19.16%
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
+1.89%+3.59%+10.56%+13.15%+38.42%
Cerevel Therapeutics Holdings, Inc. stock logo
CERE
Cerevel Therapeutics
0.00%0.00%0.00%0.00%+8.55%
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
+1.21%-0.65%+6.78%+28.34%-25.50%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Alkermes plc stock logo
ALKS
Alkermes
4.7366 of 5 stars
4.41.00.04.22.82.51.9
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
2.6532 of 5 stars
3.53.00.00.02.21.70.6
Cerevel Therapeutics Holdings, Inc. stock logo
CERE
Cerevel Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
2.4053 of 5 stars
2.22.00.00.31.31.71.3
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Alkermes plc stock logo
ALKS
Alkermes
2.83
Moderate Buy$40.0036.29% Upside
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
3.00
Buy$220.6723.21% Upside
Cerevel Therapeutics Holdings, Inc. stock logo
CERE
Cerevel Therapeutics
0.00
N/AN/AN/A
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
2.43
Hold$15.1712.17% Upside

Current Analyst Ratings Breakdown

Latest ASND, ALKS, ELAN, and CERE Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/17/2025
Alkermes plc stock logo
ALKS
Alkermes
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeNeutral ➝ Buy$33.00 ➝ $42.00
6/13/2025
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$215.00 ➝ $224.00
6/9/2025
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$201.00 ➝ $216.00
6/3/2025
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$196.00 ➝ $201.00
5/28/2025
Alkermes plc stock logo
ALKS
Alkermes
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageNeutral ➝ Buy$45.00
5/19/2025
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$15.00 ➝ $16.00
5/13/2025
Alkermes plc stock logo
ALKS
Alkermes
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
5/12/2025
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$200.00 ➝ $200.00
5/8/2025
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$13.00 ➝ $15.00
5/5/2025
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeEqual Weight ➝ Overweight$180.00 ➝ $250.00
5/2/2025
Alkermes plc stock logo
ALKS
Alkermes
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Neutral
(Data available from 6/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Alkermes plc stock logo
ALKS
Alkermes
$1.56B3.11$2.66 per share11.04$9.05 per share3.24
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
$393.54M27.82N/AN/A($1.88) per share-95.27
Cerevel Therapeutics Holdings, Inc. stock logo
CERE
Cerevel Therapeutics
N/AN/AN/AN/A$3.71 per shareN/A
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
$4.44B1.51$2.28 per share5.92$12.33 per share1.10
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Alkermes plc stock logo
ALKS
Alkermes
$367.07M$2.0914.0421.421.8023.30%27.52%17.98%7/23/2025 (Estimated)
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
-$409.12M-$6.28N/A746.25N/A-93.22%N/A-33.29%9/2/2025 (Estimated)
Cerevel Therapeutics Holdings, Inc. stock logo
CERE
Cerevel Therapeutics
-$432.84M-$2.73N/AN/AN/AN/A-98.94%-45.07%N/A
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
$338M$0.7418.2715.192.618.43%7.54%3.57%8/6/2025 (Estimated)

Latest ASND, ALKS, ELAN, and CERE Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
7/23/2025Q2 2025
Alkermes plc stock logo
ALKS
Alkermes
$0.42N/AN/AN/A$343.20 millionN/A
5/7/2025Q1 2025
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
$0.31$0.37+$0.06$0.14$1.17 billion$1.19 billion
5/1/2025Q1 2025
Alkermes plc stock logo
ALKS
Alkermes
$0.32$0.13-$0.19$0.13$307.53 million$306.51 million
5/1/2025Q1 2025
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
-$1.56-$1.66-$0.10-$1.66$98.56 million$123.97 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Alkermes plc stock logo
ALKS
Alkermes
N/AN/AN/AN/AN/A
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
N/AN/AN/AN/AN/A
Cerevel Therapeutics Holdings, Inc. stock logo
CERE
Cerevel Therapeutics
N/AN/AN/AN/AN/A
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Alkermes plc stock logo
ALKS
Alkermes
N/A
3.33
2.92
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
N/A
1.04
0.71
Cerevel Therapeutics Holdings, Inc. stock logo
CERE
Cerevel Therapeutics
0.60
10.22
10.22
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
0.68
2.71
1.46

Institutional Ownership

CompanyInstitutional Ownership
Alkermes plc stock logo
ALKS
Alkermes
95.21%
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
N/A
Cerevel Therapeutics Holdings, Inc. stock logo
CERE
Cerevel Therapeutics
87.73%
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
97.48%

Insider Ownership

CompanyInsider Ownership
Alkermes plc stock logo
ALKS
Alkermes
4.40%
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
40.00%
Cerevel Therapeutics Holdings, Inc. stock logo
CERE
Cerevel Therapeutics
5.10%
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
0.89%
CompanyEmployeesShares OutstandingFree FloatOptionable
Alkermes plc stock logo
ALKS
Alkermes
1,800164.90 million157.65 millionOptionable
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
1,01761.13 million36.68 millionOptionable
Cerevel Therapeutics Holdings, Inc. stock logo
CERE
Cerevel Therapeutics
300182.20 million172.90 millionOptionable
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
9,000496.65 million492.23 millionOptionable

Recent News About These Companies

Vets Who Can’t Solve Dogs’ Itching Lose Clients

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Alkermes stock logo

Alkermes NASDAQ:ALKS

$29.35 +0.09 (+0.31%)
Closing price 06/24/2025 04:00 PM Eastern
Extended Trading
$29.73 +0.38 (+1.31%)
As of 04:41 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; and LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.

Ascendis Pharma A/S stock logo

Ascendis Pharma A/S NASDAQ:ASND

$179.10 +3.32 (+1.89%)
Closing price 06/24/2025 04:00 PM Eastern
Extended Trading
$178.92 -0.17 (-0.10%)
As of 08:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.

Cerevel Therapeutics stock logo

Cerevel Therapeutics NASDAQ:CERE

Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, develops various therapies for neuroscience diseases in the United States. It is developing Emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-concept trial in patients with drug-resistant focal onset seizures or focal epilepsy, as well as in phase 1 trial to treat panic symptoms model. The company's products also comprise Tavapadon, a selective dopamine D1/D5 partial agonist that is in phase 3 clinical trial for the treatment of early- and late-stage Parkinson's disease; CVL-871, a selective dopamine D1/D5 partial agonist, which is in Phase 2a clinical trial to treat dementia-related apathy; and CVL-354, a selective kappa-opioid receptor antagonist to treat major depressive disorder and substance use disorder. It is also involved in the development of an M4 agonist program for the treatment of psychosis and related indications; and PDE4 inhibitor for the treatment of psychiatric, neuroinflammatory, and other disorders. Cerevel Therapeutics Holdings, Inc. was founded in 2018 and is headquartered in Cambridge, Massachusetts.

Elanco Animal Health stock logo

Elanco Animal Health NYSE:ELAN

$13.52 +0.17 (+1.28%)
Closing price 06/24/2025 03:59 PM Eastern
Extended Trading
$13.54 +0.01 (+0.10%)
As of 08:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands. The company sells its products to third-party distributors; veterinarians; and farm animal producers, including beef and dairy farmers, as well as pork, poultry, and aquaculture operations. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Greenfield, Indiana.